Adaptive Biotechnologies
ADPT
190 hedge funds and large institutions have $457M invested in Adaptive Biotechnologies in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 56 increasing their positions, 69 reducing their positions, and 37 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
1.61% less ownership
Funds ownership: 99.87% → 98.27% (-1.6%)
5% less funds holding
Funds holding: 200 → 190 (-10)
19% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 69
24% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 37
35% less capital invested
Capital invested by funds: $709M → $457M (-$251M)
98% less call options, than puts
Call options by funds: $12K | Put options by funds: $581K
Top Buyers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$29.6M |
| 2 |
Millennium Management
New York
|
+$3.23M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.06M |
| 4 |
Cerity Partners
New York
|
+$2.09M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.62M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.3M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$8.69M |
| 3 |
EHI
Eagle Health Investments
Greenwich,
Connecticut
|
-$5.95M |
| 4 |
Morgan Stanley
New York
|
-$4.71M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$3.74M |
ADPT Hedge Fund Activity: Q1 2024 in Review
190 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q1 2024, worth a combined $457M — down 35% from $709M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ADPT and 28 opened new positions — a net loss of 9 holders — while 69 trimmed existing stakes and 56 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $29.6M. The largest seller was Point72 Asset Management, cutting an estimated $13.3M.
- 190 institutional investors held Adaptive Biotechnologies (ADPT) as of Q1 2024, down from 200 in Q4 2023.
- Funds reported $457M of Adaptive Biotechnologies stock for Q1 2024, down 35% quarter-over-quarter.
- 28 funds opened new Adaptive Biotechnologies positions in Q1 2024 and 37 closed out, a net change of -9 holders.
- The largest Adaptive Biotechnologies buyer in Q1 2024 was Rubric Capital Management (New York), an estimated $29.6M added.
- The largest Adaptive Biotechnologies seller in Q1 2024 was Point72 Asset Management, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2024.